PRN: Global Antifungal Drugs Market Analysis & Trends 2013-2017 - Industry Forecast to 2025: $12.8 Billion Growth Opportunities/Investment Opportunities - Research and Markets

23/feb/2017 15:45:12 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Global Antifungal Drugs Market Analysis & Trends 2013-2017 - Industry Forecast to 2025: $12.8 Billion Growth Opportunities/Investment Opportunities - Research and Markets

 
[23-February-2017]
 

DUBLIN, Feb 23, 2017 /PRNewswire/ --


Research and Markets has announced the addition of the "Global Antifungal Drugs Market Analysis & Trends - Industry Forecast to 2025" report to their offering.

The Global Antifungal Drugs Market is poised to grow at a CAGR of around 1.8% over the next decade to reach approximately $12.8 billion by 2025.

This industry report analyzes the market estimates and forecasts for all the given segments on global as well as regional levels presented in the research scope. The study provides historical market data for 2013, 2014 revenue estimations are presented for 2015 and forecasts from 2016 till 2025.

The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies. With comprehensive market assessment across the major geographies such as North America, Europe, Asia Pacific, Middle East, Latin America and Rest of the world the report is a valuable asset for the existing players, new entrants and the future investors.

Some of the prominent trends that the market is witnessing include raising awareness amid public, developing public-private partnership in pharmaceutical industry, latest technological advancements in antifungal infection therapeutics and growth opportunities/investment opportunities.

Based on Drug type the market is categorized into polyenes, echinocandins, azoles, allylamines and other drug types. Depending on the Therapeutic Indication the market is segmented by dermatophytosis, candidiasis, aspergillosis and other therapeutic indications.

Depending on the Product form the market is segmented by tablets, shampoo, liquids or spray, injections, gels and cream. Based on Application the market is categorized into powders, pastes, ointments, drugs, other applications. Based on Distribution channel the market is categorized into retail pharmacies, hospital pharmacies, E-commerce, specialty clinics and other distribution channels.

Report Highlights:

- The report provides a detailed analysis on current and future market trends to identify the investment opportunities
- Market forecasts till 2025, using estimated market values as the base numbers
- Key market trends across the business segments, Regions and Countries
- Key developments and strategies observed in the market
- Market Dynamics such as Drivers, Restraints, Opportunities and other trends
- In-depth company profiles of key players and upcoming prominent players
- Growth prospects among the emerging nations through 2025
- Market opportunities and recommendations for new investments

Key Topics Covered:

1 Market Outline

2 Executive Summary

3 Market Overview
3.1 Current Trends
3.1.1 Raising awareness amid Public
3.1.2 Developing public-private partnership in pharmaceutical industry
3.1.3 Latest technological advancements in Antifungal infection Therapeutics
3.1.4 Growth opportunities/investment opportunities
3.2 Drivers
3.3 Constraints
3.4 Industry Attractiveness

4 Antifungal Drugs Market, By Drug Type
4.1 Polyenes
4.1.1.1 Liposomal Amphotericin B Corifungin
4.1.1.2 Natamycin
4.1.1.3 Hamycin
4.1.1.4 Candicidin
4.1.1.5 Amphotericin B Deoxycholate
4.1.1.6 Nystatin
4.1.1.7 Other Polyenes
4.2 Echinocandins
4.2.1.1 Micafungin
4.2.1.2 Caspofungin
4.2.1.3 Pneumocandins
4.2.1.4 Anidulafungin
4.2.1.5 Other Echinocandins
4.3 Azoles
4.3.1.1 Voriconazole
4.3.1.2 Posaconazole
4.3.1.3 Thiazoles
4.3.1.4 Ketoconazole
4.3.1.5 Itraconazole
4.3.1.6 Imidazoles
4.3.1.7 Fluconazole
4.3.1.8 Other Azoles
4.4 Allylamines
4.4.1.1 Terbinafine
4.4.1.2 Lamisil
4.4.1.3 Other Allylamines
4.5 Other Drug types
4.5.1.1 Greisiofulvin
4.5.1.2 Ciclopirox
4.5.1.3 Benzoic Acid

5 Antifungal Drugs Market, By Therapeutic Indication
5.1 Dermatophytosis
5.2 Candidiasis
5.3 Aspergillosis
5.4 Other Therapeutic Indications
5.4.1.1 Sporotrichosis
5.4.1.2 Pseudallescheriasis
5.4.1.3 Paracoccidioidomycosis
5.4.1.4 Onychomycosis
5.4.1.5 Histoplasmosis
5.4.1.6 Cryptococcosis
5.4.1.7 Coccidioidomycosis
5.4.1.8 Blastomycosis
5.4.1.9 Zygomycosis

6 Antifungal Drugs Market, By Product form
6.1 Tablets
6.2 Shampoo
6.3 Liquids or Spray
6.4 Injections
6.5 Gels
6.6 Cream

7 Antifungal Drugs Market, By Application
7.1 Powders
7.2 Pastes
7.3 Ointments
7.4 Drugs
7.5 Other Applications

8 Antifungal Drugs Market, By Distribution channel
8.1 Retail Pharmacies
8.2 Hospital Pharmacies
8.3 E-commerce
8.4 Specialty Clinics
8.5 Other Distribution channels
8.5.1 Other Distribution channels Market Forecast to 2025 (US$ MN)

9 Antifungal Drugs Market, By Geography

10 Key Player Activities
10.1 Acquisitions & Mergers
10.2 Agreements, Partnerships, Collaborations and Joint Ventures
10.3 Product Launch & Expansions
10.4 Other Activities

11 Leading Companies
11.1 Scynexis Inc.
11.2 Sanofi-Aventis
11.3 Pfizer Inc.
11.4 Novartis AG
11.5 Merck & Co. Inc
11.6 Kramer Laboratories
11.7 Johnson & Johnson
11.8 ID Sigma-Aldrich Corporation
11.11 Glenmark Pharmaceuticals Ltd
11.10 Glaxosmithkline
11.11 Enzon Pharmaceuticals
11.12 Bayer Healthcare
11.13 Astellas Pharma Inc
11.14 Asperqillus
11.15 Alternaria
11.16 Abbott Laboratories

For more information about this report visit http://www.researchandmarkets.com/research/lp59rk/global_antifungal

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com 

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

 



blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl